Nirsevimab administration in infants is linked to a lower risk of hospitalization for respiratory syncytial virus compared to maternal vaccination.
The study evaluated over 42,000 newborns during the 2024-2025 RSV season using the French National Health Data System.
Infants receiving nirsevimab had a 26% lower likelihood of RSV-associated lower respiratory tract infection compared to those with maternal vaccination.
Severe outcomes, including PICU admission and ventilatory support, were less common in the nirsevimab group.
The findings suggest that nirsevimab may provide better protection against RSV-related hospitalization in early infancy.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
Editor
Affiliations:
Specialties:
Areas of Expertise:
